Aerpio Pharmaceuticals – Consensus Indicates Potential 78.6% Upside

Broker Ratings

Aerpio Pharmaceuticals with ticker code (ARPO) have now 2 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 2 and 1.5 with a mean TP of 1.75. Now with the previous closing price of 0.98 this would imply there is a potential upside of 78.6%. The 50 day MA is 1.47 and the 200 day moving average is 1.4. The company has a market cap of $49m. Company Website: http://www.aerpio.com

Aerpio Pharmaceuticals, a biopharmaceutical company, focuses on developing and commercializing compounds for the treatment of ocular diseases and diabetic complications. The company’s lead product candidate is razuprotafib, a small molecule activator of the Tie2 pathway, which completed the Phase IIb clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which is in a Phase 1b clinical trial for the treatment of inflammatory bowel disease; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals has a collaboration with Quantum Leap Healthcare Collaborative for the evaluation of razuprotafib in the treatment of acute respiratory distress syndrome in adult patients with moderate to severe COVID-19. The company is headquartered in Cincinnati, Ohio.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit

AIM All Share Index